Furthermore, although FGF-21 is not strong enough as a screening marker alone and might be influenced by metabolic and inflammatory conditions, its potential to be a promising biomarker as part of a multi-biomarker blood-based panel for CRC screening should be further explored. This evidence concerns the gene FGF21 and colorectal carcinoma.